Metabolon and Massachusetts General Hospital have been awarded a contract from the National Institute of Neurological Disorders and
Stroke to research biomarkers for amyotrophic lateral sclerosis (ALS) disease.
The amount of the contract was not disclosed.
The project will seek to identify metabolic signatures for ALS that could lead to a faster, more accurate diagnostic test, Metabolon said.
“This is a continuation of Metabolon’s focus to find a faster diagnostic process for ALS that will lead to more effective therapy and potentially new therapeutics in the treatment of this devastating disease,” said John Ryals, president and CEO of Metabolon, in a statement.
Metabolon has patent-pending technology designed to track biochemical changes and to help identify safer drug compounds.